glp-1 weight loss plateau challenges TrimRX Nutritional priorities to support GLP-1

Collectively the prior work support moving forward with a Phase II, placebo-controlled study of D+Q (NCT04685590)

March 2026: Novo Nordisk reported top-line REDEFINE-1 Phase 3 CagriSema data showing 22.7% mean body weight reduction at 52 weeks , demonstrating superiority over standalone semaglutide 2.4mg and confirming the semaglutide-plus-amylin combination as clinically competitive with tirzepatide

Frasca D, Diaz A, Romero M, Landin AM, Blomberg BB

Im now at a point where Im going to buy even more clothes, says Hayley Grice, 50, from Shropshire, who has dropped seven sizes after starting on the GLP-1 weight loss jab Mounjaro two years ago